FY2025 EPS Estimates for ESPR Lifted by Cantor Fitzgerald

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Investment analysts at Cantor Fitzgerald lifted their FY2025 EPS estimates for Esperion Therapeutics in a research note issued on Wednesday, March 12th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will post earnings of $0.12 per share for the year, up from their previous forecast of $0.05. Cantor Fitzgerald currently has a “Overweight” rating and a $8.00 target price on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.29) per share.

A number of other analysts have also recently commented on ESPR. The Goldman Sachs Group started coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They set a “neutral” rating and a $4.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Esperion Therapeutics in a report on Tuesday, March 4th. Needham & Company LLC reiterated a “buy” rating and issued a $6.00 price target on shares of Esperion Therapeutics in a research report on Friday, December 13th. Finally, JMP Securities restated a “market outperform” rating and set a $4.00 target price (down previously from $7.00) on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $6.75.

Esperion Therapeutics Stock Performance

Shares of ESPR stock opened at $1.50 on Friday. Esperion Therapeutics has a 12 month low of $1.47 and a 12 month high of $3.94. The stock has a market cap of $296.77 million, a P/E ratio of -2.34 and a beta of 1.04. The company has a 50 day simple moving average of $1.89 and a two-hundred day simple moving average of $2.08.

Hedge Funds Weigh In On Esperion Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Wasatch Advisors LP raised its stake in Esperion Therapeutics by 4.9% during the fourth quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company’s stock valued at $53,861,000 after purchasing an additional 1,136,245 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Esperion Therapeutics by 4.1% in the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after acquiring an additional 171,609 shares during the period. State Street Corp raised its stake in shares of Esperion Therapeutics by 2.7% in the third quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock valued at $6,360,000 after acquiring an additional 99,802 shares during the period. Two Sigma Advisers LP raised its stake in shares of Esperion Therapeutics by 0.4% in the fourth quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company’s stock valued at $7,956,000 after acquiring an additional 16,100 shares during the period. Finally, Nuveen Asset Management LLC raised its stake in shares of Esperion Therapeutics by 48.6% in the fourth quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company’s stock valued at $6,862,000 after acquiring an additional 1,020,243 shares during the period. Institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.